Global Minimally Invasive Biopsy Technologies Market: Focus on Liquid Biopsy, Optical Biopsy, and Brush Biopsy, Fine Needle Aspiration, Pigmented Lesion Assays, and Breath Biopsy, Regulatory Scenario, Therapeutic Application, Competitive Landscape,18 Countries’ Data - Analysis and Forecast, 2019-2030
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.
Key Questions Answered in the Report:
The minimally invasive biopsy technologies market industry analysis by BIS Research projects the market to grow at a significant CAGR of 12.82% during the forecast period, 2019-2030. The minimally invasive biopsy technologies market generated $924.8 million revenue in 2018, in terms of value.
The market growth in the minimally invasive biopsy technologies market can primarily be attributed to the factors such increasing global burden of cancer, rising awareness for early disease diagnosis, and increasing demand for minimally invasive diagnostics. However, there are significant challenges which are restraining the market growth. These challenges include stringent regulatory guidelines, the high cost of technologies, and the lack of adequate reimbursement policies.
Expert Quote
“The increasing adoption of targeted therapies and the growing prominence of the concept of personalized medicine are driving the adoption of minimally invasive biopsy technologies. The increasing adoption is further expected to bring down the cost and is expected to improve the patient access to these technologies.”
Scope of the Market Intelligence on Global Minimally Invasive Biopsy Technologies Market
The research report on global minimally invasive biopsy technologies market provides a holistic view of the market in terms of various factors influencing it, including regulatory reforms and technological advancements.
The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the minimally invasive biopsy technologies market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to minimally invasive biopsy technologies market.
Market Segmentation
The global minimally invasive biopsy technologies market segmentation (on the basis of technology) is further segmented into liquid biopsy, optical biopsy, and other technologies (brush biopsy, fine needle aspiration, pigmented lesion assays, and breath biopsy).
The global liquid biopsy market is further segmented by product (tests, kits and consumables, and instruments), circulating biomarkers (ctDNA, CTCs, cfDNA, extracellular vesicles and others), clinical application (treatment monitoring, prognosis and recurrence monitoring, treatment selection, and diagnosis and screening), and therapeutic application (lung cancer, breast cancer, prostate cancer, colorectal cancer, blood cancer, other types of cancer, and non-oncology applications).
The global optical biopsy market is further segmented by therapeutic application (oncology and non-oncology applications).
The global other technologies market is further segmented by therapeutic application (lung cancer, melanoma, thyroid cancer, and non-oncology applications).
The global minimally invasive biopsy technologies market segmentation (on the basis of region) is segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East, and Rest-of-the-World. The potential of each technology with respect to different regions has also been provided.
Key Companies in the Global Minimally Invasive Biopsy Technologies Market
The key manufacturers who have been contributing significantly to the global minimally invasive biopsy technologies market include Abcodia Ltd., Adaptive Biotechnologies, Biocept, Inc., Caliber Imaging & Diagnostics, Chronix Biomedical, DermTech, F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Mauna Kea Technologies, Myriad Genetics, NeoGenomics Laboratories, Inc., Owlstone Medical Ltd, QIAGEN, Thermo Fisher Scientific, and Veracyte, Inc., among others.
Key Questions Answered in the Report:
- What are the various minimally invasive biopsy technologies available in the market?
- What are the major market drivers, challenges, and opportunities in the global minimally invasive biopsy technologies market?
- What is the current market size and future potential of these technologies?
- How is the integration of AI expected to impact the market growth during the forecast period?
- What is the role of minimally invasive biopsy technologies in drug discovery and clinical research?
- How are minimally invasive biopsy technologies expected to drive precision medicine during the forecast period?
- How are technologies such as optical biopsy, breath biopsy, and skin assays expected to evolve in the future?
- What are the guidelines implemented by different government bodies to regulate the approval of minimally invasive biopsy technologies?
- Which are the established as well as emerging players in this market and what key strategies are being followed by them to establish a strong foothold in the market?
- Which therapeutic application market is estimated to witness massive incorporation of the minimally invasive biopsy technologies market in the forecast period?
- Which clinical application is expected to dominate the market during the forecast period?
- Which technological advancements are expected to impact the market growth in the future?
The minimally invasive biopsy technologies market industry analysis by BIS Research projects the market to grow at a significant CAGR of 12.82% during the forecast period, 2019-2030. The minimally invasive biopsy technologies market generated $924.8 million revenue in 2018, in terms of value.
The market growth in the minimally invasive biopsy technologies market can primarily be attributed to the factors such increasing global burden of cancer, rising awareness for early disease diagnosis, and increasing demand for minimally invasive diagnostics. However, there are significant challenges which are restraining the market growth. These challenges include stringent regulatory guidelines, the high cost of technologies, and the lack of adequate reimbursement policies.
Expert Quote
“The increasing adoption of targeted therapies and the growing prominence of the concept of personalized medicine are driving the adoption of minimally invasive biopsy technologies. The increasing adoption is further expected to bring down the cost and is expected to improve the patient access to these technologies.”
Scope of the Market Intelligence on Global Minimally Invasive Biopsy Technologies Market
The research report on global minimally invasive biopsy technologies market provides a holistic view of the market in terms of various factors influencing it, including regulatory reforms and technological advancements.
The scope of this report is centered upon conducting a detailed study of the products and manufacturers allied with the minimally invasive biopsy technologies market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to minimally invasive biopsy technologies market.
Market Segmentation
The global minimally invasive biopsy technologies market segmentation (on the basis of technology) is further segmented into liquid biopsy, optical biopsy, and other technologies (brush biopsy, fine needle aspiration, pigmented lesion assays, and breath biopsy).
The global liquid biopsy market is further segmented by product (tests, kits and consumables, and instruments), circulating biomarkers (ctDNA, CTCs, cfDNA, extracellular vesicles and others), clinical application (treatment monitoring, prognosis and recurrence monitoring, treatment selection, and diagnosis and screening), and therapeutic application (lung cancer, breast cancer, prostate cancer, colorectal cancer, blood cancer, other types of cancer, and non-oncology applications).
The global optical biopsy market is further segmented by therapeutic application (oncology and non-oncology applications).
The global other technologies market is further segmented by therapeutic application (lung cancer, melanoma, thyroid cancer, and non-oncology applications).
The global minimally invasive biopsy technologies market segmentation (on the basis of region) is segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East, and Rest-of-the-World. The potential of each technology with respect to different regions has also been provided.
Key Companies in the Global Minimally Invasive Biopsy Technologies Market
The key manufacturers who have been contributing significantly to the global minimally invasive biopsy technologies market include Abcodia Ltd., Adaptive Biotechnologies, Biocept, Inc., Caliber Imaging & Diagnostics, Chronix Biomedical, DermTech, F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Mauna Kea Technologies, Myriad Genetics, NeoGenomics Laboratories, Inc., Owlstone Medical Ltd, QIAGEN, Thermo Fisher Scientific, and Veracyte, Inc., among others.
EXECUTIVE SUMMARY
1 PRODUCT DEFINITION
1.1 Inclusions and Exclusions
2 RESEARCH SCOPE
2.1 Scope of Work
2.2 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 Global Minimally Invasive Biopsy Technologies Market: Research Methodology
3.1.1 Primary Data Sources
3.1.2 Secondary Data Sources
3.1.3 Selection Criteria for Company Profiles
4 INDUSTRY ANALYSIS
4.1 Industry Ecosystem
4.2 Regulatory Framework and Government Initiatives
4.2.1 Liquid Biopsy: Regulatory Framework
4.2.1.1 Liquid Biopsy: Regulations in the U.S.
4.2.1.2 Liquid Biopsy: Regulations in Other Countries
4.2.2 Optical Biopsy and Other Technologies: Regulatory Framework
4.2.2.1 Optical Biopsy and Other Technologies: Regulations in the U.S.
4.2.2.2 Optical Biopsy and Other Technologies: Regulations in the Europe
4.2.2.3 Optical Biopsy and Other Technologies: Regulations in Other Countries
4.3 Patent Analysis
4.3.1 Liquid Biopsy: Patent Analysis
4.3.2 Optical Biopsy: Patent Analysis
4.4 Physician’s Perception
5 COMPETITIVE LANDSCAPE
5.1 Key strategies and Developments
5.1.1 Partnerships, Alliances, and Business Expansions
5.1.2 New Offerings
5.1.3 Funding Activities
5.1.4 Procurement and Sales Agreements
5.1.5 Regulatory and Legal Developments
5.1.6 Mergers and Acquisitions
5.2 Market Share Analysis
5.2.1 Market Share Analysis: Global Liquid Biopsy Market
5.2.2 Market Share Analysis: Global Optical Biopsy Market
5.2.3 Market Share Analysis: Global Other Technologies Market
5.3 Growth Share Analysis
5.3.1 Growth Share Matrix (by Technology)
5.3.2 Growth Share Matrix (by Therapeutic Application)
5.3.3 Growth Share Matrix (by Region)
6 GLOBAL MINIMALLY INVASIVE BIOPSY TECHNOLOGIES MARKET, 2018-2030
6.1 Assumptions and Limitations
6.2 Key Findings and Opportunity Assessment
6.3 Global Minimally Invasive Biopsy Technologies, Market Scenario
6.3.1 Global Minimally Invasive Biopsy Technologies Market Size and Forecast (2018-2030)
6.3.2 Market Dynamics
6.3.2.1 Overview
6.3.2.2 Impact Analysis
6.3.2.3 Market Drivers
6.3.2.3.1 Rising Global Burden of Cancer
6.3.2.3.2 Increasing Number of Cross-Industry Collaborations
6.3.2.3.3 Growing Prominence of Precision Medicine
6.3.2.4 Market Restraints
6.3.2.4.1 Uncertain Regulatory Requirements
6.3.2.4.2 Lack of Favorable Reimbursement Policies
6.3.2.4.3 Technical Challenges Associated with the Analysis of Circulating Biomarkers
6.3.2.5 Market Opportunities
6.3.2.5.1 Business Expansion in Emerging Economies
6.3.2.5.2 Integration of Artificial Intelligence (AI)
6.3.2.5.3 Rising Number of Initiatives by the Government
6.4 Market Estimation Method
7 GLOBAL MINIMALLY INVASIVE BIOPSY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2018-2030
7.1 Overview
7.2 Global Liquid Biopsy Market Scenario, 2018-2030
7.2.1 Principle and Advantages of Liquid Biopsy
7.2.2 Key Findings and Opportunity Assessment
7.2.3 Global Liquid Biopsy Market, Market Size and Forecast (2018-2030)
7.2.3.1 Market Dynamics
7.2.3.1.1 Impact Analysis
7.2.3.1.2 Market Drivers
7.2.3.1.2.1 Increasing Demand for Liquid Biopsy Tests
7.2.3.1.2.2 Recent Product Launches and Approvals
7.2.3.1.2.3 Strong Pipeline
7.2.3.1.3 Market Restraints
7.2.3.1.3.1 Uncertain Regulatory Requirements
7.2.3.1.3.2 Lack of Adequate Reimbursement
7.2.4 Global Liquid Biopsy Market Segmentation
7.2.4.1 Global Liquid Biopsy Market (by Product), 2018-2030
7.2.4.1.1 Overview
7.2.4.1.2 Tests
7.2.4.1.3 Kits and Consumables
7.2.4.1.4 Instruments
7.2.4.2 Global Liquid Biopsy Market, by Circulating Biomarker, Market Size and Forecast (2018-2030)
7.2.4.2.1 Overview
7.2.4.2.2 Circulating Tumor DNA (ctDNA)
7.2.4.2.3 Circulating Tumor Cells (CTCs)
7.2.4.2.4 Cell-Free DNA (cfDNA)
7.2.4.2.5 Extracellular Vesicles and Others
7.2.4.3 Global Liquid Biopsy Market, by Clinical Application, Market Size and Forecast (2018-2030)
7.2.4.3.1 Overview
7.2.4.3.2 Treatment Monitoring
7.2.4.3.3 Prognosis and Recurrence Monitoring
7.2.4.3.4 Treatment Selection
7.2.4.3.5 Diagnosis and Screening
7.2.4.4 Global Liquid Biopsy Market, by Therapeutic Application, Market Size and Forecast (2018-2030)
7.2.4.4.1 Overview
7.2.4.4.2 Lung Cancer
7.2.4.4.3 Breast Cancer
7.2.4.4.4 Prostate Cancer
7.2.4.4.5 Colorectal Cancer
7.2.4.4.6 Blood Cancer
7.2.4.4.7 Other Types of Cancer
7.2.4.4.8 Non-Oncology Applications
7.3 Global Optical Biopsy Market Scenario, 2018-2030
7.3.1 Principle and Advantages of Optical Biopsy
7.3.2 Key Findings and Opportunity Assessment
7.3.3 Global Optical Biopsy Market, Market Size and Forecast (2018-2030)
7.3.3.1 Market Dynamics
7.3.3.1.1 Impact Analysis
7.3.3.1.2 Market Drivers
7.3.3.1.2.1 Recent Product Launches and Approvals
7.3.3.1.2.2 Significant Number of Funding and Investments
7.3.3.1.2.3 Anticipated Product Launches
7.3.3.1.3 Market Restraints
7.3.3.1.3.1 Lack of Favorable Reimbursement
7.3.3.1.3.2 Stringent Regulatory Guidelines
7.3.4 Global Optical Biopsy Market (by Therapeutic Application), 2018-2030
7.3.4.1 Overview
7.3.4.2 Oncology
7.3.4.3 Non-Oncology Applications
7.4 Global Other Technologies Market Scenario, 2018-2030
7.4.1 Overview
7.4.2 Key Findings and Opportunity Assessment
7.4.3 Global Other Technologies Market, Market Size and Forecast (2018-2030)
7.4.3.1 Market Dynamics
7.4.3.1.1 Impact Analysis
7.4.3.1.2 Market Drivers
7.4.3.1.2.1 Ongoing Strategic Collaborations and M&A Activities
7.4.3.1.2.2 Strong Product Pipeline
7.4.3.1.3 Market Restraints
7.4.3.1.3.1 Poor Reimbursement Scenario
7.4.3.1.3.2 Limited Scope of Expansion in Emerging Economies
7.4.4 Global Other Technologies Market, (by Therapeutic Application)
7.4.4.1 Overview
7.4.4.2 Lung Cancer
7.4.4.3 Melanoma
7.4.4.4 Thyroid Cancer
7.4.4.5 Non-Oncology Applications
8 GLOBAL MINIMALLY INVASIVE BIOPSY TECHNOLOGIES MARKET, (BY REGION), 2018-2030
8.1 Overview and Key Findings
8.2 North America
8.2.1 Market Footprint: North America Minimally Invasive Biopsy Technologies Market
8.2.1.1 Market Dynamics
8.2.1.1.1 Impact Analysis
8.2.2 North America: Liquid Biopsy Market
8.2.2.1 North America: Liquid Biopsy Market, By Country
8.2.2.1.1 U.S.
8.2.2.1.2 Canada
8.2.3 North America: Optical Biopsy Market
8.2.3.1 North America: Optical Biopsy Market, by Country
8.2.3.1.1 U.S.
8.2.3.1.2 Canada
8.2.4 North America: Other Technologies Market
8.2.4.1 North America: Other Technologies Market, By Country
8.2.4.1.1 U.S.
8.2.4.1.2 Canada
8.3 Europe
8.3.1 Market Footprint: Europe Minimally Invasive Biopsy Technologies Market
8.3.1.1 Market Dynamics
8.3.1.1.1 Impact Analysis
8.3.2 Europe: Liquid Biopsy Market
8.3.2.1 Europe: Liquid Biopsy Market, By Country
8.3.2.1.1 Germany
8.3.2.1.2 France
8.3.2.1.3 U.K.
8.3.2.1.4 Italy
8.3.2.1.5 Spain
8.3.2.1.6 Rest-of-Europe
8.3.3 Europe: Optical Biopsy Market
8.3.3.1 Europe: Optical Biopsy Market, by Country
8.3.3.1.1 Germany
8.3.3.1.2 U.K.
8.3.3.1.3 France
8.3.3.1.4 Netherlands
8.3.3.1.5 Rest-of-Europe
8.3.4 Europe: Other Technologies Market
8.3.4.1 Europe: Other Technologies Market, By Country
8.3.4.1.1 U.K.
8.3.4.1.2 Germany
8.3.4.1.3 Switzerland
8.4 Asia-Pacific
8.4.1 Market Footprint: Asia-Pacific Minimally Invasive Biopsy Technologies Market
8.4.1.1 Market Dynamics
8.4.1.1.1 Impact Analysis
8.4.2 Asia-Pacific: Liquid Biopsy Market
8.4.2.1 Asia-Pacific: Liquid Biopsy Market, by Country
8.4.2.1.1 China
8.4.2.1.2 Japan
8.4.2.1.3 India
8.4.2.1.4 Australia
8.4.2.1.5 South Korea
8.4.2.1.6 Singapore
8.4.2.1.7 Rest-of-Asia-Pacific
8.4.3 Asia-Pacific: Optical Biopsy Market
8.4.3.1 Asia-Pacific: Optical Biopsy Market, by Country
8.4.3.1.1 Japan
8.4.3.1.2 China
8.4.3.1.3 South Korea
8.4.3.1.4 Rest-of Asia-Pacific
8.5 Latin America and the Middle East
8.5.1 Market Footprint: Latin America and the Middle East Minimally Invasive Biopsy Technologies Market
8.5.1.1 Market Dynamics
8.5.1.1.1 Impact Analysis
8.5.2 Latin America and the Middle East: Liquid Biopsy Market
8.5.2.1 Latin America and the Middle East: Liquid Biopsy Market, By Country
8.5.2.1.1 Brazil
8.5.2.1.2 Mexico
8.5.2.1.3 Saudi Arabia
8.5.2.1.4 Rest-of-Latin America and the Middle East
8.5.3 Latin America and the Middle East: Optical Biopsy Market
8.6 Rest-of-the-World
8.6.1 Market Footprint: Rest-of-the-World Minimally Invasive Biopsy Technologies Market
8.6.1.1 Market Dynamics
8.6.1.1.1 Impact Analysis
8.6.2 Rest-of-the-World: Liquid Biopsy Market
8.6.3 Rest-of-the-World: Optical Biopsy Market
9 COMPANY PROFILES
9.1 Abcodia Ltd.
9.1.1 Company Overview
9.1.1 Role of Abcodia Ltd. in the Global Minimally Invasive Biopsy Technologies Market
9.1.2 SWOT Analysis: Abcodia Ltd.
9.2 Adaptive Biotechnologies
9.2.1 Company Overview
9.2.2 Role of Adaptive Biotechnologies in the Global Minimally Invasive Biopsy Technologies Market
9.2.3 Financials
9.2.4 SWOT Analysis: Adaptive Biotechnologies
9.3 Biocept, Inc.
9.3.1 Company Overview
9.3.2 Role of Biocept, Inc. in the Global Minimally Invasive Biopsy Technologies Market
9.3.3 Financials
9.3.3.1 Key Insights on the Financial Health of the Company
9.3.4 SWOT Analysis: Biocept, Inc.
9.4 Caliber Imaging & Diagnostics
9.4.1 Company Overview
9.4.2 Role of Caliber Imaging & Diagnostics in the Global Minimally Invasive Biopsy Technologies Market
9.4.3 SWOT Analysis: Caliber Imaging & Diagnostics
9.5 Chronix Biomedical
9.5.1 Company Overview
9.5.2 Role of Chronix Biomedical in the Global Minimally Invasive Biopsy Technologies Market
9.5.3 SWOT Analysis: Chronix Biomedical
9.6 DermTech
9.6.1 Company Overview
9.6.2 Role of DermTech in the Global Minimally Invasive Biopsy Technologies Market
9.6.3 Financials
9.6.3.1 Key Insights on the Financial Health of the Company
9.6.4 SWOT Analysis: DermTech
9.7 F. Hoffmann-La Roche Ltd
9.7.1 Company Overview
9.7.2 Role of F. Hoffmann-La Roche Ltd in the Global Minimally Invasive Biopsy Technologies Market
9.7.3 Financials
9.7.3.1 Key Insights on the Financial Health of the Company
9.7.4 SWOT Analysis: F. Hoffmann-La Roche Ltd
9.8 Guardant Health, Inc.
9.8.1 Company Overview
9.8.2 Role of Guardant Health, Inc. in the Global Minimally Invasive Biopsy Technologies Market
9.8.3 Financials
9.8.3.1 Key Insights on the Financial Health of the Company
9.8.4 SWOT Analysis: Guardant Health, Inc.
9.9 Mauna Kea Technologies
9.9.1 Company Overview
9.9.2 Role of Mauna Kea Technologies in the Global Minimally Invasive Biopsy Technologies Market
9.9.3 Financials
9.9.3.1 Key Insights on the Financial Health of the Company
9.9.4 SWOT Analysis: Mauna Kea Technologies
9.10 Myriad Genetics
9.10.1 Company Overview
9.10.2 Role of Myriad Genetics in the Global Minimally Invasive Biopsy Technologies Market
9.10.3 Financials
9.10.3.1 Key Insights on the Financial Health of the Company
9.10.4 SWOT Analysis: Myriad Genetics
9.11 NeoGenomics Laboratories, Inc.
9.11.1 Company Overview
9.11.2 Role of NeoGenomics Laboratories, Inc. in the Global Minimally Invasive Biopsy Technologies Market
9.11.3 Financials
9.11.3.1 Key Insights on the Financial Health of the Company
9.11.4 SWOT Analysis: NeoGenomics Laboratories, Inc.
9.12 Owlstone Medical Ltd
9.12.1 Company Overview
9.12.2 Role of Owlstone Medical Ltd in the Global Minimally Invasive Biopsy Technologies Market
9.12.3 SWOT Analysis: Owlstone Medical Ltd
9.13 QIAGEN
9.13.1 Company Overview
9.13.2 Role of QIAGEN in the Global Minimally Invasive Biopsy Technologies Market
9.13.3 Financials
9.13.3.1 Key Insights on the Financial Health of the Company
9.13.4 SWOT Analysis: QIAGEN
9.14 Thermo Fisher Scientific
9.14.1 Company Overview
9.14.2 Role of Thermo Fisher Scientific in the Global Minimally Invasive Biopsy Technologies Market
9.14.3 Financials
9.14.3.1 Key Insights on the Financial Health of the Company
9.14.4 SWOT Analysis: Thermo Fisher Scientific
9.15 Veracyte, Inc.
9.15.1 Company Overview
9.15.2 Role of Veracyte, Inc. in the Global Minimally Invasive Biopsy Technologies Market
9.15.3 Financials
9.15.3.1 Key Insights on the Financial Health of the Company
9.15.4 SWOT Analysis: Veracyte, Inc.
1 PRODUCT DEFINITION
1.1 Inclusions and Exclusions
2 RESEARCH SCOPE
2.1 Scope of Work
2.2 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 Global Minimally Invasive Biopsy Technologies Market: Research Methodology
3.1.1 Primary Data Sources
3.1.2 Secondary Data Sources
3.1.3 Selection Criteria for Company Profiles
4 INDUSTRY ANALYSIS
4.1 Industry Ecosystem
4.2 Regulatory Framework and Government Initiatives
4.2.1 Liquid Biopsy: Regulatory Framework
4.2.1.1 Liquid Biopsy: Regulations in the U.S.
4.2.1.2 Liquid Biopsy: Regulations in Other Countries
4.2.2 Optical Biopsy and Other Technologies: Regulatory Framework
4.2.2.1 Optical Biopsy and Other Technologies: Regulations in the U.S.
4.2.2.2 Optical Biopsy and Other Technologies: Regulations in the Europe
4.2.2.3 Optical Biopsy and Other Technologies: Regulations in Other Countries
4.3 Patent Analysis
4.3.1 Liquid Biopsy: Patent Analysis
4.3.2 Optical Biopsy: Patent Analysis
4.4 Physician’s Perception
5 COMPETITIVE LANDSCAPE
5.1 Key strategies and Developments
5.1.1 Partnerships, Alliances, and Business Expansions
5.1.2 New Offerings
5.1.3 Funding Activities
5.1.4 Procurement and Sales Agreements
5.1.5 Regulatory and Legal Developments
5.1.6 Mergers and Acquisitions
5.2 Market Share Analysis
5.2.1 Market Share Analysis: Global Liquid Biopsy Market
5.2.2 Market Share Analysis: Global Optical Biopsy Market
5.2.3 Market Share Analysis: Global Other Technologies Market
5.3 Growth Share Analysis
5.3.1 Growth Share Matrix (by Technology)
5.3.2 Growth Share Matrix (by Therapeutic Application)
5.3.3 Growth Share Matrix (by Region)
6 GLOBAL MINIMALLY INVASIVE BIOPSY TECHNOLOGIES MARKET, 2018-2030
6.1 Assumptions and Limitations
6.2 Key Findings and Opportunity Assessment
6.3 Global Minimally Invasive Biopsy Technologies, Market Scenario
6.3.1 Global Minimally Invasive Biopsy Technologies Market Size and Forecast (2018-2030)
6.3.2 Market Dynamics
6.3.2.1 Overview
6.3.2.2 Impact Analysis
6.3.2.3 Market Drivers
6.3.2.3.1 Rising Global Burden of Cancer
6.3.2.3.2 Increasing Number of Cross-Industry Collaborations
6.3.2.3.3 Growing Prominence of Precision Medicine
6.3.2.4 Market Restraints
6.3.2.4.1 Uncertain Regulatory Requirements
6.3.2.4.2 Lack of Favorable Reimbursement Policies
6.3.2.4.3 Technical Challenges Associated with the Analysis of Circulating Biomarkers
6.3.2.5 Market Opportunities
6.3.2.5.1 Business Expansion in Emerging Economies
6.3.2.5.2 Integration of Artificial Intelligence (AI)
6.3.2.5.3 Rising Number of Initiatives by the Government
6.4 Market Estimation Method
7 GLOBAL MINIMALLY INVASIVE BIOPSY TECHNOLOGIES MARKET, BY TECHNOLOGY, 2018-2030
7.1 Overview
7.2 Global Liquid Biopsy Market Scenario, 2018-2030
7.2.1 Principle and Advantages of Liquid Biopsy
7.2.2 Key Findings and Opportunity Assessment
7.2.3 Global Liquid Biopsy Market, Market Size and Forecast (2018-2030)
7.2.3.1 Market Dynamics
7.2.3.1.1 Impact Analysis
7.2.3.1.2 Market Drivers
7.2.3.1.2.1 Increasing Demand for Liquid Biopsy Tests
7.2.3.1.2.2 Recent Product Launches and Approvals
7.2.3.1.2.3 Strong Pipeline
7.2.3.1.3 Market Restraints
7.2.3.1.3.1 Uncertain Regulatory Requirements
7.2.3.1.3.2 Lack of Adequate Reimbursement
7.2.4 Global Liquid Biopsy Market Segmentation
7.2.4.1 Global Liquid Biopsy Market (by Product), 2018-2030
7.2.4.1.1 Overview
7.2.4.1.2 Tests
7.2.4.1.3 Kits and Consumables
7.2.4.1.4 Instruments
7.2.4.2 Global Liquid Biopsy Market, by Circulating Biomarker, Market Size and Forecast (2018-2030)
7.2.4.2.1 Overview
7.2.4.2.2 Circulating Tumor DNA (ctDNA)
7.2.4.2.3 Circulating Tumor Cells (CTCs)
7.2.4.2.4 Cell-Free DNA (cfDNA)
7.2.4.2.5 Extracellular Vesicles and Others
7.2.4.3 Global Liquid Biopsy Market, by Clinical Application, Market Size and Forecast (2018-2030)
7.2.4.3.1 Overview
7.2.4.3.2 Treatment Monitoring
7.2.4.3.3 Prognosis and Recurrence Monitoring
7.2.4.3.4 Treatment Selection
7.2.4.3.5 Diagnosis and Screening
7.2.4.4 Global Liquid Biopsy Market, by Therapeutic Application, Market Size and Forecast (2018-2030)
7.2.4.4.1 Overview
7.2.4.4.2 Lung Cancer
7.2.4.4.3 Breast Cancer
7.2.4.4.4 Prostate Cancer
7.2.4.4.5 Colorectal Cancer
7.2.4.4.6 Blood Cancer
7.2.4.4.7 Other Types of Cancer
7.2.4.4.8 Non-Oncology Applications
7.3 Global Optical Biopsy Market Scenario, 2018-2030
7.3.1 Principle and Advantages of Optical Biopsy
7.3.2 Key Findings and Opportunity Assessment
7.3.3 Global Optical Biopsy Market, Market Size and Forecast (2018-2030)
7.3.3.1 Market Dynamics
7.3.3.1.1 Impact Analysis
7.3.3.1.2 Market Drivers
7.3.3.1.2.1 Recent Product Launches and Approvals
7.3.3.1.2.2 Significant Number of Funding and Investments
7.3.3.1.2.3 Anticipated Product Launches
7.3.3.1.3 Market Restraints
7.3.3.1.3.1 Lack of Favorable Reimbursement
7.3.3.1.3.2 Stringent Regulatory Guidelines
7.3.4 Global Optical Biopsy Market (by Therapeutic Application), 2018-2030
7.3.4.1 Overview
7.3.4.2 Oncology
7.3.4.3 Non-Oncology Applications
7.4 Global Other Technologies Market Scenario, 2018-2030
7.4.1 Overview
7.4.2 Key Findings and Opportunity Assessment
7.4.3 Global Other Technologies Market, Market Size and Forecast (2018-2030)
7.4.3.1 Market Dynamics
7.4.3.1.1 Impact Analysis
7.4.3.1.2 Market Drivers
7.4.3.1.2.1 Ongoing Strategic Collaborations and M&A Activities
7.4.3.1.2.2 Strong Product Pipeline
7.4.3.1.3 Market Restraints
7.4.3.1.3.1 Poor Reimbursement Scenario
7.4.3.1.3.2 Limited Scope of Expansion in Emerging Economies
7.4.4 Global Other Technologies Market, (by Therapeutic Application)
7.4.4.1 Overview
7.4.4.2 Lung Cancer
7.4.4.3 Melanoma
7.4.4.4 Thyroid Cancer
7.4.4.5 Non-Oncology Applications
8 GLOBAL MINIMALLY INVASIVE BIOPSY TECHNOLOGIES MARKET, (BY REGION), 2018-2030
8.1 Overview and Key Findings
8.2 North America
8.2.1 Market Footprint: North America Minimally Invasive Biopsy Technologies Market
8.2.1.1 Market Dynamics
8.2.1.1.1 Impact Analysis
8.2.2 North America: Liquid Biopsy Market
8.2.2.1 North America: Liquid Biopsy Market, By Country
8.2.2.1.1 U.S.
8.2.2.1.2 Canada
8.2.3 North America: Optical Biopsy Market
8.2.3.1 North America: Optical Biopsy Market, by Country
8.2.3.1.1 U.S.
8.2.3.1.2 Canada
8.2.4 North America: Other Technologies Market
8.2.4.1 North America: Other Technologies Market, By Country
8.2.4.1.1 U.S.
8.2.4.1.2 Canada
8.3 Europe
8.3.1 Market Footprint: Europe Minimally Invasive Biopsy Technologies Market
8.3.1.1 Market Dynamics
8.3.1.1.1 Impact Analysis
8.3.2 Europe: Liquid Biopsy Market
8.3.2.1 Europe: Liquid Biopsy Market, By Country
8.3.2.1.1 Germany
8.3.2.1.2 France
8.3.2.1.3 U.K.
8.3.2.1.4 Italy
8.3.2.1.5 Spain
8.3.2.1.6 Rest-of-Europe
8.3.3 Europe: Optical Biopsy Market
8.3.3.1 Europe: Optical Biopsy Market, by Country
8.3.3.1.1 Germany
8.3.3.1.2 U.K.
8.3.3.1.3 France
8.3.3.1.4 Netherlands
8.3.3.1.5 Rest-of-Europe
8.3.4 Europe: Other Technologies Market
8.3.4.1 Europe: Other Technologies Market, By Country
8.3.4.1.1 U.K.
8.3.4.1.2 Germany
8.3.4.1.3 Switzerland
8.4 Asia-Pacific
8.4.1 Market Footprint: Asia-Pacific Minimally Invasive Biopsy Technologies Market
8.4.1.1 Market Dynamics
8.4.1.1.1 Impact Analysis
8.4.2 Asia-Pacific: Liquid Biopsy Market
8.4.2.1 Asia-Pacific: Liquid Biopsy Market, by Country
8.4.2.1.1 China
8.4.2.1.2 Japan
8.4.2.1.3 India
8.4.2.1.4 Australia
8.4.2.1.5 South Korea
8.4.2.1.6 Singapore
8.4.2.1.7 Rest-of-Asia-Pacific
8.4.3 Asia-Pacific: Optical Biopsy Market
8.4.3.1 Asia-Pacific: Optical Biopsy Market, by Country
8.4.3.1.1 Japan
8.4.3.1.2 China
8.4.3.1.3 South Korea
8.4.3.1.4 Rest-of Asia-Pacific
8.5 Latin America and the Middle East
8.5.1 Market Footprint: Latin America and the Middle East Minimally Invasive Biopsy Technologies Market
8.5.1.1 Market Dynamics
8.5.1.1.1 Impact Analysis
8.5.2 Latin America and the Middle East: Liquid Biopsy Market
8.5.2.1 Latin America and the Middle East: Liquid Biopsy Market, By Country
8.5.2.1.1 Brazil
8.5.2.1.2 Mexico
8.5.2.1.3 Saudi Arabia
8.5.2.1.4 Rest-of-Latin America and the Middle East
8.5.3 Latin America and the Middle East: Optical Biopsy Market
8.6 Rest-of-the-World
8.6.1 Market Footprint: Rest-of-the-World Minimally Invasive Biopsy Technologies Market
8.6.1.1 Market Dynamics
8.6.1.1.1 Impact Analysis
8.6.2 Rest-of-the-World: Liquid Biopsy Market
8.6.3 Rest-of-the-World: Optical Biopsy Market
9 COMPANY PROFILES
9.1 Abcodia Ltd.
9.1.1 Company Overview
9.1.1 Role of Abcodia Ltd. in the Global Minimally Invasive Biopsy Technologies Market
9.1.2 SWOT Analysis: Abcodia Ltd.
9.2 Adaptive Biotechnologies
9.2.1 Company Overview
9.2.2 Role of Adaptive Biotechnologies in the Global Minimally Invasive Biopsy Technologies Market
9.2.3 Financials
9.2.4 SWOT Analysis: Adaptive Biotechnologies
9.3 Biocept, Inc.
9.3.1 Company Overview
9.3.2 Role of Biocept, Inc. in the Global Minimally Invasive Biopsy Technologies Market
9.3.3 Financials
9.3.3.1 Key Insights on the Financial Health of the Company
9.3.4 SWOT Analysis: Biocept, Inc.
9.4 Caliber Imaging & Diagnostics
9.4.1 Company Overview
9.4.2 Role of Caliber Imaging & Diagnostics in the Global Minimally Invasive Biopsy Technologies Market
9.4.3 SWOT Analysis: Caliber Imaging & Diagnostics
9.5 Chronix Biomedical
9.5.1 Company Overview
9.5.2 Role of Chronix Biomedical in the Global Minimally Invasive Biopsy Technologies Market
9.5.3 SWOT Analysis: Chronix Biomedical
9.6 DermTech
9.6.1 Company Overview
9.6.2 Role of DermTech in the Global Minimally Invasive Biopsy Technologies Market
9.6.3 Financials
9.6.3.1 Key Insights on the Financial Health of the Company
9.6.4 SWOT Analysis: DermTech
9.7 F. Hoffmann-La Roche Ltd
9.7.1 Company Overview
9.7.2 Role of F. Hoffmann-La Roche Ltd in the Global Minimally Invasive Biopsy Technologies Market
9.7.3 Financials
9.7.3.1 Key Insights on the Financial Health of the Company
9.7.4 SWOT Analysis: F. Hoffmann-La Roche Ltd
9.8 Guardant Health, Inc.
9.8.1 Company Overview
9.8.2 Role of Guardant Health, Inc. in the Global Minimally Invasive Biopsy Technologies Market
9.8.3 Financials
9.8.3.1 Key Insights on the Financial Health of the Company
9.8.4 SWOT Analysis: Guardant Health, Inc.
9.9 Mauna Kea Technologies
9.9.1 Company Overview
9.9.2 Role of Mauna Kea Technologies in the Global Minimally Invasive Biopsy Technologies Market
9.9.3 Financials
9.9.3.1 Key Insights on the Financial Health of the Company
9.9.4 SWOT Analysis: Mauna Kea Technologies
9.10 Myriad Genetics
9.10.1 Company Overview
9.10.2 Role of Myriad Genetics in the Global Minimally Invasive Biopsy Technologies Market
9.10.3 Financials
9.10.3.1 Key Insights on the Financial Health of the Company
9.10.4 SWOT Analysis: Myriad Genetics
9.11 NeoGenomics Laboratories, Inc.
9.11.1 Company Overview
9.11.2 Role of NeoGenomics Laboratories, Inc. in the Global Minimally Invasive Biopsy Technologies Market
9.11.3 Financials
9.11.3.1 Key Insights on the Financial Health of the Company
9.11.4 SWOT Analysis: NeoGenomics Laboratories, Inc.
9.12 Owlstone Medical Ltd
9.12.1 Company Overview
9.12.2 Role of Owlstone Medical Ltd in the Global Minimally Invasive Biopsy Technologies Market
9.12.3 SWOT Analysis: Owlstone Medical Ltd
9.13 QIAGEN
9.13.1 Company Overview
9.13.2 Role of QIAGEN in the Global Minimally Invasive Biopsy Technologies Market
9.13.3 Financials
9.13.3.1 Key Insights on the Financial Health of the Company
9.13.4 SWOT Analysis: QIAGEN
9.14 Thermo Fisher Scientific
9.14.1 Company Overview
9.14.2 Role of Thermo Fisher Scientific in the Global Minimally Invasive Biopsy Technologies Market
9.14.3 Financials
9.14.3.1 Key Insights on the Financial Health of the Company
9.14.4 SWOT Analysis: Thermo Fisher Scientific
9.15 Veracyte, Inc.
9.15.1 Company Overview
9.15.2 Role of Veracyte, Inc. in the Global Minimally Invasive Biopsy Technologies Market
9.15.3 Financials
9.15.3.1 Key Insights on the Financial Health of the Company
9.15.4 SWOT Analysis: Veracyte, Inc.
LIST OF TABLES
Table 4.1: Guidance Documents for the FDA Approval of Liquid Biopsies
Table 4.2: Regulatory Bodies in Other Countries
Table 6.1: Market Drivers
Table 6.2: Market Restraints
Table 6.3: Global Cancer Statistics (by Region), 2018
Table 6.4: National Expenditures for Cancer Care in the U.S. ($Billion)
Table 6.5: 5-Year Prevalence (2018) of Major Cancer Types
Table 7.1: Market Drivers
Table 7.2: Market Restraints
Table 7.3: Liquid Biopsy: Recent Launches and Approvals
Table 7.4: Liquid Biopsy: Pipeline
Table 7.5: Market Drivers
Table 7.6: Market Restraints
Table 7.7: Optical Biopsy: Recent Launches and Approvals
Table 7.8: Market Drivers
Table 7.9: Market Restraints
Table 7.10: Pipeline Products
Table 8.1: Market Drivers
Table 8.2: Market Restraints
Table 8.3: Market Drivers
Table 8.4: Market Restraints
Table 8.6: Market Drivers
Table 8.7: Market Restraints
Table 8.8: Market Drivers
Table 8.9: Market Restraints
Table 8.10: Market Drivers
Table 8.11: Market Restraints
Table 4.1: Guidance Documents for the FDA Approval of Liquid Biopsies
Table 4.2: Regulatory Bodies in Other Countries
Table 6.1: Market Drivers
Table 6.2: Market Restraints
Table 6.3: Global Cancer Statistics (by Region), 2018
Table 6.4: National Expenditures for Cancer Care in the U.S. ($Billion)
Table 6.5: 5-Year Prevalence (2018) of Major Cancer Types
Table 7.1: Market Drivers
Table 7.2: Market Restraints
Table 7.3: Liquid Biopsy: Recent Launches and Approvals
Table 7.4: Liquid Biopsy: Pipeline
Table 7.5: Market Drivers
Table 7.6: Market Restraints
Table 7.7: Optical Biopsy: Recent Launches and Approvals
Table 7.8: Market Drivers
Table 7.9: Market Restraints
Table 7.10: Pipeline Products
Table 8.1: Market Drivers
Table 8.2: Market Restraints
Table 8.3: Market Drivers
Table 8.4: Market Restraints
Table 8.6: Market Drivers
Table 8.7: Market Restraints
Table 8.8: Market Drivers
Table 8.9: Market Restraints
Table 8.10: Market Drivers
Table 8.11: Market Restraints
LIST OF FIGURES
Figure 1: Global Minimally Invasive Biopsy Technologies Market, 2018-2030
Figure 2: Impact Analysis of Market Drivers and Market Restraints, 2018-2030
Figure 3: Leading Players in the Global Minimally Invasive Biopsy Technologies Market
Figure 4: Share of Key Developments and Strategies, January 2015-December 2019
Figure 2.1: Global Minimally Invasive Biopsy Technologies Market Segmentation
Figure 3.1: Research Methodology
Figure 3.2: Primary Research
Figure 3.3: Secondary Research
Figure 3.4: Data Triangulation
Figure 3.5: Bottom-up Approach (Segment-Wise Analysis)
Figure 3.6: Top-Down Approach (Segment-Wise Analysis)
Figure 3.7: Assumptions and Limitations
Figure 3.8: Considered Factors for Data Prediction and Modelling
Figure 3.9: Shares of Key Company Profiles
Figure 4.1: Industry Ecosystem
Figure 4.2: Evolution of FDA Guidelines for the Approval of Companion Diagnostics
Figure 4.3: Number of Patents in Liquid Biopsy (2011-2019)
Figure 4.4: Number of Patents in Optical Biopsy (2011-2019)
Figure 5.1: Share of Key Developments and Strategies, January 2015-December 2019
Figure 5.2: Share of Partnerships, Alliances and Business Expansions, January 2015-December 2019
Figure 5.3: Share of New Offerings, January 2015-December 2019
Figure 5.4: Share of Funding Activities, January 2015-December 2019
Figure 5.5: Share of Procurement and Sales Agreements, January 2015-December 2019
Figure 5.6: Share of Regulatory and Legal Developments, January 2015-December 2019
Figure 5.7: Share of Mergers and Acquisitions, January 2015-December 2019
Figure 5.8: Market Share Analysis: Global Liquid Biopsy Market, 2018
Figure 5.9: Market Share Analysis: Global Liquid Biopsy Market, 2017
Figure 5.10: Market Share Analysis: Global Optical Biopsy Market, 2018
Figure 5.11: Market Share Analysis: Global Optical Biopsy Market, 2018
Figure 5.12: Market Share Analysis: Global Other Technologies Market, 2018
Figure 5.13: Market Share Analysis: Global Other Technologies Market, 2017
Figure 5.14: Growth Share Matrix: Global Minimally Invasive Biopsy Technologies Market (by Technology), 2018-2030
Figure 5.15: Growth Share Matrix: Global Minimally Invasive Biopsy Technologies Market (by Therapeutic Application), 2018-2030
Figure 5.16: Growth Share Matrix: Global Minimally Invasive Biopsy Technologies Market (by Region), 2018-2030
Figure 6.1: Global Minimally Invasive Biopsy Technologies Market, 2030 Opportunity Assessment
Figure 6.2: Global Minimally Invasive Biopsy Technologies Market, 2018-2030
Figure 7.1: Global Minimally Invasive Biopsy Technologies Market (by Technology), 2018-2030
Figure 7.2: Global Liquid Biopsy Market, 2030 Opportunity Assessment
Figure 7.3: Global Liquid Biopsy Market, 2018-2030
Figure 7.4: Global Liquid Biopsy Market Segmentation
Figure 7.5: Global Liquid Biopsy Market (by Product), 2018-2030
Figure 7.6: Global Liquid Biopsy Market (by Tests), 2018-2030
Figure 7.7: Global Liquid Biopsy Market (by Kits and Consumables), 2018-2030
Figure 7.8: Global Liquid Biopsy Market (by Instruments), 2018-2030
Figure 7.9: Global Liquid Biopsy Market (by Circulating Biomarkers), 2018-2030
Figure 7.10: Global Liquid Biopsy Market (by ctDNA), 2018-2030
Figure 7.11: Global Liquid Biopsy Market (by CTCs), 2018-2030
Figure 7.12: Global Liquid Biopsy Market (by cfDNA), 2018-2030
Figure 7.13: Global Liquid Biopsy Market (by Extracellular Vesicles and Others), 2018-2030
Figure 7.14: Global Liquid Biopsy Market (by Clinical Application), 2018-2030
Figure 7.15: Global Liquid Biopsy Market (by Treatment Monitoring), 2018-2030
Figure 7.16: Global Liquid Biopsy Market (by Prognosis and Recurrence Monitoring), 2018-2030
Figure 7.17: Global Liquid Biopsy Market (by Treatment Selection), 2018-2030
Figure 7.18: Global Liquid Biopsy Market (by Diagnosis and Screening), 2018-2030
Figure 7.19: Global Liquid Biopsy Market (by Therapeutic Application), 2018-2030
Figure 7.20: Global Liquid Biopsy Market (by Lung Cancer), 2018-2030
Figure 7.21: Global Liquid Biopsy Market (by Breast Cancer), 2018-2030
Figure 7.22: Global Liquid Biopsy Market (by Prostate Cancer), 2018-2030
Figure 7.23: Global Liquid Biopsy Market (by Colorectal Cancer), 2018-2030
Figure 7.24: Global Liquid Biopsy Market (by Blood Cancer), 2018-2030
Figure 7.25: Global Liquid Biopsy Market (by Other Types of Cancer), 2018-2030
Figure 7.26: Global Liquid Biopsy Market (by Non-Oncology Applications), 2018-2030
Figure 7.27: Global Optical Biopsy Market, 2030 Opportunity Assessment
Figure 7.28: Global Optical Biopsy Market, 2018-2030
Figure 7.29: Global Optical Biopsy Market (by Therapeutic Application), 2018-2030
Figure 7.30: Global Optical Biopsy Market (by Oncology), 2018-2030
Figure 7.31: Global Optical Biopsy Market (by Oncology), 2018-2030
Figure 7.32: Other Technologies
Figure 7.33: Global Other Technologies Market, 2030 Opportunity Assessment
Figure 7.34: Global Other Technologies Market, 2018-2030
Figure 7.35: Global Other Technologies Market (by Therapeutic Application), 2018-2030
Figure 7.36: Global Other Technologies Market (by Lung Cancer), 2018-2030
Figure 7.37: Global Other Technologies Market (by Melanoma), 2018-2030
Figure 7.38: Global Other Technologies Market (by Thyroid Cancer), 2018-2030
Figure 7.39: Global Other Technologies Market (by Non-Oncology Applications), 2018-2030
Figure 8.1: Global Minimally Invasive Biopsy Technologies Market Scenario, 2018 and 2030
Figure 8.2: North America: Minimally Invasive Biopsy Technologies Market, 2018-2030
Figure 8.3: North America: Liquid Biopsy Market, 2018-2030
Figure 8.4: North America: Liquid Biopsy Market Dynamics
Figure 8.5: North America: Liquid Biopsy Market (by Country), 2018-2030
Figure 8.6: U.S.: Liquid Biopsy Market, 2018-2030
Figure 8.7: Canada: Liquid Biopsy Market, 2018-2030
Figure 8.8: North America: Optical Biopsy Market, 2018-2030
Figure 8.9: North America: Optical Biopsy Market Dynamics
Figure 8.10: North America: Optical Biopsy Market (by Country), 2018-2030
Figure 8.11: U.S.: Optical Biopsy Market, 2018-2030
Figure 8.12: Canada: Optical Biopsy Market, 2018-2030
Figure 8.13: North America: Other Technologies Market, 2018-2030
Figure 8.14: North America: Other Technologies Market Dynamics
Figure 8.15: North America: Other Technologies Market (by Country), 2018-2030
Figure 8.16: U.S.: Other Technologies Market, 2018-2030
Figure 8.17: Canada: Other Technologies Market, 2018-2030
Figure 8.18: Europe: Minimally Invasive Biopsy Technologies Market, 2018-2030
Figure 8.19: Europe: Liquid Biopsy Market, 2018-2030
Figure 8.20: Europe: Liquid Biopsy Market Dynamics
Figure 8.21: Europe: Liquid Biopsy Market (by Country), 2018-2030
Figure 8.22: Germany: Liquid Biopsy Market, 2018-2030
Figure 8.23: France: Liquid Biopsy Market, 2018-2030
Figure 8.24: U.K.: Liquid Biopsy Market, 2018-2030
Figure 8.25: Italy: Liquid Biopsy Market, 2018-2030
Figure 8.26: Spain: Liquid Biopsy Market, 2018-2030
Figure 8.27: Rest-of-Europe: Liquid Biopsy Market, 2018-2030
Figure 8.28: Europe: Optical Biopsy Market, 2018-2030
Figure 8.29: Europe: Optical Biopsy Market Dynamics
Figure 8.30: Europe: Optical Biopsy Market (by Country), 2018-2030
Figure 8.31: Germany: Optical Biopsy Market, 2018-2030
Figure 8.32: U.K.: Optical Biopsy Market, 2018-2030
Figure 8.33: France: Optical Biopsy Market, 2018-2030
Figure 8.34: Netherlands: Optical Biopsy Market, 2018-2030
Figure 8.35: Rest-of-Europe: Optical Biopsy Market, 2018-2030
Figure 8.36: Europe: Other Technologies Market, 2018-2030
Figure 8.37: Europe: Other Technologies Market Dynamics
Figure 8.38: Europe: Other Technologies Market (by Country), 2018-2030
Figure 8.39: U.K: Other Technologies Market, 2018-2030
Figure 8.40: Germany: Other Technologies Market, 2018-2030
Figure 8.41: Switzerland: Other Technologies Market, 2018-2030
Figure 8.42: Asia-Pacific: Minimally Invasive Biopsy Technologies Market, 2018-2030
Figure 8.43: Asia-Pacific: Liquid Biopsy Market, 2018-2030
Figure 8.44: Asia-Pacific: Liquid Biopsy Market Dynamics
Figure 8.45: Asia-Pacific: Liquid Biopsy Market (by Country), 2018-2030
Figure 8.46: China: Liquid Biopsy Market, 2018-2030
Figure 8.47: Japan: Liquid Biopsy Market, 2018-2030
Figure 8.48: India: Liquid Biopsy Market, 2018-2030
Figure 8.49: Australia: Liquid Biopsy Market, 2018-2030
Figure 8.50: South Korea: Liquid Biopsy Market, 2018-2030
Figure 8.51: Singapore: Liquid Biopsy Market, 2018-2030
Figure 8.52: Rest-of-Asia-Pacific: Liquid Biopsy Market, 2018-2030
Figure 8.53: Asia-Pacific: Optical Biopsy Market, 2018-2030
Figure 8.54: Asia-Pacific: Optical Biopsy Market Dynamics
Figure 8.55: Asia-Pacific: Optical Biopsy Market (by Country), 2018-2030
Figure 8.56: Japan: Optical Biopsy Market, 2018-2030
Figure 8.57: China: Optical Biopsy Market, 2018-2030
Figure 8.58: South Korea: Optical Biopsy Market, 2018-2030
Figure 8.59: Rest-of-Asia-Pacific: Optical Biopsy Market, 2018-2030
Figure 8.60: Latin America and the Middle East: Minimally Invasive Biopsy Technologies Market, 2018-2030
Figure 8.61: Latin America and the Middle East: Liquid Biopsy Market, 2018-2030
Figure 8.62: Latin America and the Middle East: Liquid Biopsy Market Dynamics
Figure 8.63: Latin America and the Middle East: Liquid Biopsy Market (by Country), 2018-2030
Figure 8.64: Brazil: Liquid Biopsy Market, 2018-2030
Figure 8.65: Mexico: Liquid Biopsy Market, 2018-2030
Figure 8.66: Saudi Arabia: Liquid Biopsy Market, 2018-2030
Figure 8.67: Rest-of-Latin America and the Middle East: Liquid Biopsy Market, 2018-2030
Figure 8.68: Latin America and the Middle East: Optical Biopsy Market, 2018-2030
Figure 8.69: Rest-of-the-World: Minimally Invasive Biopsy Technologies Market, 2018-2030
Figure 8.70: Rest-of-the-World: Liquid Biopsy Market, 2018-2030
Figure 8.71: Rest-of-the-World: Optical Biopsy Market, 2018-2030
Figure 9.1: Abcodia Ltd.: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.2: Adaptive Biotechnologies: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.3: Adaptive Biotechnologies Net Revenue (by Business Segment), 2017 and 2018
Figure 9.4: Biocept, Inc.: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.5: Biocept, Inc.: Overall Financials, 2016-2018
Figure 9.6: Biocept, Inc.: R&D Expense, 2016-2018
Figure 9.7: Caliber Imaging & Diagnostics: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.8: Chronix Biomedical: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.9: DermTech: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.10: DermTech: Financials (Nine Months Ended September 2018-2019
Figure 9.11: DermTech: R&D Expense, 2016-2018
Figure 9.12: F. Hoffmann-La Roche Ltd: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.13: F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
Figure 9.14: F. Hoffmann-La Roche Ltd Net Revenue (by Business Segment), 2016-2018
Figure 9.15: F. Hoffmann-La Roche Ltd: Net Revenue (by Region), 2016-2018
Figure 9.16: F. Hoffmann-La Roche Ltd: R&D Expense, 2016-2018
Figure 9.17: Guardant Health, Inc.: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.18: Guardant Health, Inc.: Overall Financials, 2016-2018
Figure 9.19: Guardant Health, Inc.: Net Revenue (by Segment), 2016-2018
Figure 9.20: Guardant Health, Inc.: Net Revenue (by Region), 2016-2018
Figure 9.21: Guardant Health, Inc.: R&D Expense, 2016-2018
Figure 9.22: Mauna Kea Technologies: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.23: Mauna Kea Technologies: Overall Financials, 2016-2018
Figure 9.24: Mauna Kea Technologies Net Revenue (by Activity), 2016-2018
Figure 9.25: Mauna Kea Technologies: Net Revenue (by Region), 2016-2018
Figure 9.26: Mauna Kea Technologies: R&D Expense, 2016-2018
Figure 9.27: Myriad Genetics: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.28: Myriad Genetics: Overall Financials, 2016-2018
Figure 9.29: Myriad Genetics Net Revenue (by Business Segment), 2016-2018
Figure 9.30: Myriad Genetics: R&D Expense, 2016-2018
Figure 9.31: NeoGenomics Laboratories, Inc.: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.32: NeoGenomics Laboratories, Inc.: Overall Financials, 2016-2018
Figure 9.33: NeoGenomics Laboratories, Inc. Net Revenue (by Business Segment), 2016-2018
Figure 9.34: NeoGenomics Laboratories, Inc.: R&D Expense, 2016-2018
Figure 9.35: Owlstone Medical Ltd: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.36: QIAGEN: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.37: QIAGEN: Overall Financials, 2016-2018
Figure 9.38: QIAGEN Net Revenue (by Product Category), 2016-2018
Figure 9.39: QIAGEN Net Revenue (by Customer Class), 2016-2018
Figure 9.40: QIAGEN Net Revenue (by Region), 2016-2018
Figure 9.41: QIAGEN: R&D Expense, 2016-2018
Figure 9.42: Thermo Fisher Scientific: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.43: Thermo Fisher Scientific: Overall Financials, 2016-2018
Figure 9.44: Thermo Fisher Scientific Net Revenue (by Business Segment), 2016-2018
Figure 9.45: Thermo Fisher Scientific: Net Revenue (by Region), 2016-2018
Figure 9.46: Thermo Fisher Scientific: R&D Expense, 2016-2018
Figure 9.47: Veracyte, Inc.: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.48: Veracyte, Inc.: Overall Financials, 2016-2018
Figure 9.49: Veracyte, Inc.: R&D Expense, 2016-2018
Figure 1: Global Minimally Invasive Biopsy Technologies Market, 2018-2030
Figure 2: Impact Analysis of Market Drivers and Market Restraints, 2018-2030
Figure 3: Leading Players in the Global Minimally Invasive Biopsy Technologies Market
Figure 4: Share of Key Developments and Strategies, January 2015-December 2019
Figure 2.1: Global Minimally Invasive Biopsy Technologies Market Segmentation
Figure 3.1: Research Methodology
Figure 3.2: Primary Research
Figure 3.3: Secondary Research
Figure 3.4: Data Triangulation
Figure 3.5: Bottom-up Approach (Segment-Wise Analysis)
Figure 3.6: Top-Down Approach (Segment-Wise Analysis)
Figure 3.7: Assumptions and Limitations
Figure 3.8: Considered Factors for Data Prediction and Modelling
Figure 3.9: Shares of Key Company Profiles
Figure 4.1: Industry Ecosystem
Figure 4.2: Evolution of FDA Guidelines for the Approval of Companion Diagnostics
Figure 4.3: Number of Patents in Liquid Biopsy (2011-2019)
Figure 4.4: Number of Patents in Optical Biopsy (2011-2019)
Figure 5.1: Share of Key Developments and Strategies, January 2015-December 2019
Figure 5.2: Share of Partnerships, Alliances and Business Expansions, January 2015-December 2019
Figure 5.3: Share of New Offerings, January 2015-December 2019
Figure 5.4: Share of Funding Activities, January 2015-December 2019
Figure 5.5: Share of Procurement and Sales Agreements, January 2015-December 2019
Figure 5.6: Share of Regulatory and Legal Developments, January 2015-December 2019
Figure 5.7: Share of Mergers and Acquisitions, January 2015-December 2019
Figure 5.8: Market Share Analysis: Global Liquid Biopsy Market, 2018
Figure 5.9: Market Share Analysis: Global Liquid Biopsy Market, 2017
Figure 5.10: Market Share Analysis: Global Optical Biopsy Market, 2018
Figure 5.11: Market Share Analysis: Global Optical Biopsy Market, 2018
Figure 5.12: Market Share Analysis: Global Other Technologies Market, 2018
Figure 5.13: Market Share Analysis: Global Other Technologies Market, 2017
Figure 5.14: Growth Share Matrix: Global Minimally Invasive Biopsy Technologies Market (by Technology), 2018-2030
Figure 5.15: Growth Share Matrix: Global Minimally Invasive Biopsy Technologies Market (by Therapeutic Application), 2018-2030
Figure 5.16: Growth Share Matrix: Global Minimally Invasive Biopsy Technologies Market (by Region), 2018-2030
Figure 6.1: Global Minimally Invasive Biopsy Technologies Market, 2030 Opportunity Assessment
Figure 6.2: Global Minimally Invasive Biopsy Technologies Market, 2018-2030
Figure 7.1: Global Minimally Invasive Biopsy Technologies Market (by Technology), 2018-2030
Figure 7.2: Global Liquid Biopsy Market, 2030 Opportunity Assessment
Figure 7.3: Global Liquid Biopsy Market, 2018-2030
Figure 7.4: Global Liquid Biopsy Market Segmentation
Figure 7.5: Global Liquid Biopsy Market (by Product), 2018-2030
Figure 7.6: Global Liquid Biopsy Market (by Tests), 2018-2030
Figure 7.7: Global Liquid Biopsy Market (by Kits and Consumables), 2018-2030
Figure 7.8: Global Liquid Biopsy Market (by Instruments), 2018-2030
Figure 7.9: Global Liquid Biopsy Market (by Circulating Biomarkers), 2018-2030
Figure 7.10: Global Liquid Biopsy Market (by ctDNA), 2018-2030
Figure 7.11: Global Liquid Biopsy Market (by CTCs), 2018-2030
Figure 7.12: Global Liquid Biopsy Market (by cfDNA), 2018-2030
Figure 7.13: Global Liquid Biopsy Market (by Extracellular Vesicles and Others), 2018-2030
Figure 7.14: Global Liquid Biopsy Market (by Clinical Application), 2018-2030
Figure 7.15: Global Liquid Biopsy Market (by Treatment Monitoring), 2018-2030
Figure 7.16: Global Liquid Biopsy Market (by Prognosis and Recurrence Monitoring), 2018-2030
Figure 7.17: Global Liquid Biopsy Market (by Treatment Selection), 2018-2030
Figure 7.18: Global Liquid Biopsy Market (by Diagnosis and Screening), 2018-2030
Figure 7.19: Global Liquid Biopsy Market (by Therapeutic Application), 2018-2030
Figure 7.20: Global Liquid Biopsy Market (by Lung Cancer), 2018-2030
Figure 7.21: Global Liquid Biopsy Market (by Breast Cancer), 2018-2030
Figure 7.22: Global Liquid Biopsy Market (by Prostate Cancer), 2018-2030
Figure 7.23: Global Liquid Biopsy Market (by Colorectal Cancer), 2018-2030
Figure 7.24: Global Liquid Biopsy Market (by Blood Cancer), 2018-2030
Figure 7.25: Global Liquid Biopsy Market (by Other Types of Cancer), 2018-2030
Figure 7.26: Global Liquid Biopsy Market (by Non-Oncology Applications), 2018-2030
Figure 7.27: Global Optical Biopsy Market, 2030 Opportunity Assessment
Figure 7.28: Global Optical Biopsy Market, 2018-2030
Figure 7.29: Global Optical Biopsy Market (by Therapeutic Application), 2018-2030
Figure 7.30: Global Optical Biopsy Market (by Oncology), 2018-2030
Figure 7.31: Global Optical Biopsy Market (by Oncology), 2018-2030
Figure 7.32: Other Technologies
Figure 7.33: Global Other Technologies Market, 2030 Opportunity Assessment
Figure 7.34: Global Other Technologies Market, 2018-2030
Figure 7.35: Global Other Technologies Market (by Therapeutic Application), 2018-2030
Figure 7.36: Global Other Technologies Market (by Lung Cancer), 2018-2030
Figure 7.37: Global Other Technologies Market (by Melanoma), 2018-2030
Figure 7.38: Global Other Technologies Market (by Thyroid Cancer), 2018-2030
Figure 7.39: Global Other Technologies Market (by Non-Oncology Applications), 2018-2030
Figure 8.1: Global Minimally Invasive Biopsy Technologies Market Scenario, 2018 and 2030
Figure 8.2: North America: Minimally Invasive Biopsy Technologies Market, 2018-2030
Figure 8.3: North America: Liquid Biopsy Market, 2018-2030
Figure 8.4: North America: Liquid Biopsy Market Dynamics
Figure 8.5: North America: Liquid Biopsy Market (by Country), 2018-2030
Figure 8.6: U.S.: Liquid Biopsy Market, 2018-2030
Figure 8.7: Canada: Liquid Biopsy Market, 2018-2030
Figure 8.8: North America: Optical Biopsy Market, 2018-2030
Figure 8.9: North America: Optical Biopsy Market Dynamics
Figure 8.10: North America: Optical Biopsy Market (by Country), 2018-2030
Figure 8.11: U.S.: Optical Biopsy Market, 2018-2030
Figure 8.12: Canada: Optical Biopsy Market, 2018-2030
Figure 8.13: North America: Other Technologies Market, 2018-2030
Figure 8.14: North America: Other Technologies Market Dynamics
Figure 8.15: North America: Other Technologies Market (by Country), 2018-2030
Figure 8.16: U.S.: Other Technologies Market, 2018-2030
Figure 8.17: Canada: Other Technologies Market, 2018-2030
Figure 8.18: Europe: Minimally Invasive Biopsy Technologies Market, 2018-2030
Figure 8.19: Europe: Liquid Biopsy Market, 2018-2030
Figure 8.20: Europe: Liquid Biopsy Market Dynamics
Figure 8.21: Europe: Liquid Biopsy Market (by Country), 2018-2030
Figure 8.22: Germany: Liquid Biopsy Market, 2018-2030
Figure 8.23: France: Liquid Biopsy Market, 2018-2030
Figure 8.24: U.K.: Liquid Biopsy Market, 2018-2030
Figure 8.25: Italy: Liquid Biopsy Market, 2018-2030
Figure 8.26: Spain: Liquid Biopsy Market, 2018-2030
Figure 8.27: Rest-of-Europe: Liquid Biopsy Market, 2018-2030
Figure 8.28: Europe: Optical Biopsy Market, 2018-2030
Figure 8.29: Europe: Optical Biopsy Market Dynamics
Figure 8.30: Europe: Optical Biopsy Market (by Country), 2018-2030
Figure 8.31: Germany: Optical Biopsy Market, 2018-2030
Figure 8.32: U.K.: Optical Biopsy Market, 2018-2030
Figure 8.33: France: Optical Biopsy Market, 2018-2030
Figure 8.34: Netherlands: Optical Biopsy Market, 2018-2030
Figure 8.35: Rest-of-Europe: Optical Biopsy Market, 2018-2030
Figure 8.36: Europe: Other Technologies Market, 2018-2030
Figure 8.37: Europe: Other Technologies Market Dynamics
Figure 8.38: Europe: Other Technologies Market (by Country), 2018-2030
Figure 8.39: U.K: Other Technologies Market, 2018-2030
Figure 8.40: Germany: Other Technologies Market, 2018-2030
Figure 8.41: Switzerland: Other Technologies Market, 2018-2030
Figure 8.42: Asia-Pacific: Minimally Invasive Biopsy Technologies Market, 2018-2030
Figure 8.43: Asia-Pacific: Liquid Biopsy Market, 2018-2030
Figure 8.44: Asia-Pacific: Liquid Biopsy Market Dynamics
Figure 8.45: Asia-Pacific: Liquid Biopsy Market (by Country), 2018-2030
Figure 8.46: China: Liquid Biopsy Market, 2018-2030
Figure 8.47: Japan: Liquid Biopsy Market, 2018-2030
Figure 8.48: India: Liquid Biopsy Market, 2018-2030
Figure 8.49: Australia: Liquid Biopsy Market, 2018-2030
Figure 8.50: South Korea: Liquid Biopsy Market, 2018-2030
Figure 8.51: Singapore: Liquid Biopsy Market, 2018-2030
Figure 8.52: Rest-of-Asia-Pacific: Liquid Biopsy Market, 2018-2030
Figure 8.53: Asia-Pacific: Optical Biopsy Market, 2018-2030
Figure 8.54: Asia-Pacific: Optical Biopsy Market Dynamics
Figure 8.55: Asia-Pacific: Optical Biopsy Market (by Country), 2018-2030
Figure 8.56: Japan: Optical Biopsy Market, 2018-2030
Figure 8.57: China: Optical Biopsy Market, 2018-2030
Figure 8.58: South Korea: Optical Biopsy Market, 2018-2030
Figure 8.59: Rest-of-Asia-Pacific: Optical Biopsy Market, 2018-2030
Figure 8.60: Latin America and the Middle East: Minimally Invasive Biopsy Technologies Market, 2018-2030
Figure 8.61: Latin America and the Middle East: Liquid Biopsy Market, 2018-2030
Figure 8.62: Latin America and the Middle East: Liquid Biopsy Market Dynamics
Figure 8.63: Latin America and the Middle East: Liquid Biopsy Market (by Country), 2018-2030
Figure 8.64: Brazil: Liquid Biopsy Market, 2018-2030
Figure 8.65: Mexico: Liquid Biopsy Market, 2018-2030
Figure 8.66: Saudi Arabia: Liquid Biopsy Market, 2018-2030
Figure 8.67: Rest-of-Latin America and the Middle East: Liquid Biopsy Market, 2018-2030
Figure 8.68: Latin America and the Middle East: Optical Biopsy Market, 2018-2030
Figure 8.69: Rest-of-the-World: Minimally Invasive Biopsy Technologies Market, 2018-2030
Figure 8.70: Rest-of-the-World: Liquid Biopsy Market, 2018-2030
Figure 8.71: Rest-of-the-World: Optical Biopsy Market, 2018-2030
Figure 9.1: Abcodia Ltd.: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.2: Adaptive Biotechnologies: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.3: Adaptive Biotechnologies Net Revenue (by Business Segment), 2017 and 2018
Figure 9.4: Biocept, Inc.: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.5: Biocept, Inc.: Overall Financials, 2016-2018
Figure 9.6: Biocept, Inc.: R&D Expense, 2016-2018
Figure 9.7: Caliber Imaging & Diagnostics: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.8: Chronix Biomedical: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.9: DermTech: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.10: DermTech: Financials (Nine Months Ended September 2018-2019
Figure 9.11: DermTech: R&D Expense, 2016-2018
Figure 9.12: F. Hoffmann-La Roche Ltd: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.13: F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
Figure 9.14: F. Hoffmann-La Roche Ltd Net Revenue (by Business Segment), 2016-2018
Figure 9.15: F. Hoffmann-La Roche Ltd: Net Revenue (by Region), 2016-2018
Figure 9.16: F. Hoffmann-La Roche Ltd: R&D Expense, 2016-2018
Figure 9.17: Guardant Health, Inc.: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.18: Guardant Health, Inc.: Overall Financials, 2016-2018
Figure 9.19: Guardant Health, Inc.: Net Revenue (by Segment), 2016-2018
Figure 9.20: Guardant Health, Inc.: Net Revenue (by Region), 2016-2018
Figure 9.21: Guardant Health, Inc.: R&D Expense, 2016-2018
Figure 9.22: Mauna Kea Technologies: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.23: Mauna Kea Technologies: Overall Financials, 2016-2018
Figure 9.24: Mauna Kea Technologies Net Revenue (by Activity), 2016-2018
Figure 9.25: Mauna Kea Technologies: Net Revenue (by Region), 2016-2018
Figure 9.26: Mauna Kea Technologies: R&D Expense, 2016-2018
Figure 9.27: Myriad Genetics: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.28: Myriad Genetics: Overall Financials, 2016-2018
Figure 9.29: Myriad Genetics Net Revenue (by Business Segment), 2016-2018
Figure 9.30: Myriad Genetics: R&D Expense, 2016-2018
Figure 9.31: NeoGenomics Laboratories, Inc.: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.32: NeoGenomics Laboratories, Inc.: Overall Financials, 2016-2018
Figure 9.33: NeoGenomics Laboratories, Inc. Net Revenue (by Business Segment), 2016-2018
Figure 9.34: NeoGenomics Laboratories, Inc.: R&D Expense, 2016-2018
Figure 9.35: Owlstone Medical Ltd: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.36: QIAGEN: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.37: QIAGEN: Overall Financials, 2016-2018
Figure 9.38: QIAGEN Net Revenue (by Product Category), 2016-2018
Figure 9.39: QIAGEN Net Revenue (by Customer Class), 2016-2018
Figure 9.40: QIAGEN Net Revenue (by Region), 2016-2018
Figure 9.41: QIAGEN: R&D Expense, 2016-2018
Figure 9.42: Thermo Fisher Scientific: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.43: Thermo Fisher Scientific: Overall Financials, 2016-2018
Figure 9.44: Thermo Fisher Scientific Net Revenue (by Business Segment), 2016-2018
Figure 9.45: Thermo Fisher Scientific: Net Revenue (by Region), 2016-2018
Figure 9.46: Thermo Fisher Scientific: R&D Expense, 2016-2018
Figure 9.47: Veracyte, Inc.: Product Offerings for the Global Minimally Invasive Biopsy Technologies Market
Figure 9.48: Veracyte, Inc.: Overall Financials, 2016-2018
Figure 9.49: Veracyte, Inc.: R&D Expense, 2016-2018
